HC Wainwright Issues Optimistic Outlook for VIR Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.54) for the quarter, up from their previous estimate of ($0.84). HC Wainwright has a "Buy" rating and a $110.00 price target on the stock. The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology's Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.48) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.78) EPS and FY2029 earnings at ($1.37) EPS.

Several other equities analysts have also weighed in on VIR. Needham & Company LLC reiterated a "buy" rating and set a $14.00 price objective on shares of Vir Biotechnology in a report on Thursday, May 22nd. Barclays increased their target price on Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group reduced their target price on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $32.86.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock traded up $0.15 during trading on Thursday, hitting $4.65. The company's stock had a trading volume of 468,149 shares, compared to its average volume of 1,380,415. The stock has a market cap of $642.67 million, a price-to-earnings ratio of -1.18 and a beta of 1.36. Vir Biotechnology has a 52 week low of $4.32 and a 52 week high of $14.45. The stock has a 50-day moving average price of $5.67 and a two-hundred day moving average price of $7.63.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The business had revenue of $3.03 million during the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm's quarterly revenue was down 94.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.48) earnings per share.

Insider Buying and Selling

In other Vir Biotechnology news, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the sale, the chief executive officer now owns 769,505 shares in the company, valued at $4,578,554.75. The trade was a 9.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now owns 79,460 shares in the company, valued at approximately $726,264.40. The trade was a 8.49% decrease in their position. The disclosure for this sale can be found here. 16.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new position in shares of Vir Biotechnology in the first quarter worth $335,000. Focus Partners Wealth raised its holdings in shares of Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company's stock worth $125,000 after buying an additional 2,566 shares during the last quarter. SCS Capital Management LLC purchased a new position in shares of Vir Biotechnology in the first quarter worth $157,000. Woodline Partners LP raised its holdings in shares of Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company's stock worth $3,024,000 after buying an additional 331,701 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company's stock worth $4,813,000 after buying an additional 225,544 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company's stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).